Our Pricing

Mounjaro vs Wegovy: Which Weight Loss Treatment Is More Effective?

When comparing mounjaro vs wegovy, clinical trial data reveals important differences in effectiveness, mechanism of action, and weight loss outcomes. Both medications represent the most advanced prescription weight loss treatments available in the UK, yet they work through distinct pathways and deliver different results. Understanding these evidence-based differences helps patients and prescribers make informed decisions tailored to individual health profiles and weight loss goals.

How Mounjaro vs Wegovy Work: Mechanism of Action Compared

The fundamental difference in mounjaro vs wegovy lies in their receptor activity. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, meaning it activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors [1]. This dual action enhances insulin secretion, reduces glucagon release, slows gastric emptying, and significantly suppresses appetite through central nervous system pathways.

Wegovy (semaglutide) functions as a selective GLP-1 receptor agonist, targeting only the GLP-1 pathway [2]. Whilst highly effective, this single-receptor mechanism provides a more focused approach compared to Mounjaro's dual-action system. Both medications mimic natural gut hormones that regulate blood sugar and appetite, but tirzepatide's additional GIP activity appears to amplify metabolic benefits and weight reduction beyond GLP-1 alone.

Clinical Trial Results: Mounjaro vs Wegovy Effectiveness Data

Head-to-head mounjaro vs wegovy efficacy data from the SURPASS and STEP trials demonstrates measurable differences in weight loss outcomes. In the SURMOUNT-1 trial, Mounjaro participants achieved average weight loss of 15-21% of initial body weight over 72 weeks, depending on dose (5mg, 10mg, or 15mg weekly) [1]. The highest dose delivered a mean reduction of 20.9% body weight in adults with obesity.

Wegovy clinical trials (STEP programme) showed participants lost an average of 10-15% of body weight over 68 weeks on the 2.4mg weekly maintenance dose [2]. Whilst this represents substantial and clinically significant weight reduction, Mounjaro's dual-receptor mechanism consistently delivered 5-6 percentage points greater weight loss in comparative analyses. Both treatments significantly outperform older weight loss medications and lifestyle intervention alone.

Real-World Effectiveness Beyond Clinical Trials

Real-world evidence supports the mounjaro vs wegovy trial findings. UK prescribers report that patients on Mounjaro maintenance doses (10-15mg) typically experience more pronounced appetite suppression and faster initial weight loss compared to Wegovy 2.4mg [3]. However, individual response varies considerably based on metabolic health, adherence, dietary patterns, and concurrent medications. Both treatments require ongoing clinical monitoring and lifestyle modification to optimise outcomes and maintain weight loss long-term.

Side Effects Profile: Mounjaro vs Wegovy Tolerability

When evaluating mounjaro vs wegovy side effects, both medications share a similar gastrointestinal adverse event profile due to their GLP-1 activity. The most commonly reported side effects include nausea (affecting 20-44% of users), vomiting, diarrhoea, constipation, and abdominal discomfort [1][2]. These effects typically occur during dose escalation and often diminish as the body adapts to treatment.

Mounjaro's dual-receptor mechanism may produce slightly higher rates of gastrointestinal side effects compared to Wegovy, particularly at higher doses (15mg weekly) [3]. However, the difference is modest and both medications follow gradual dose titration schedules specifically designed to minimise adverse events. Serious side effects are rare but include pancreatitis risk, gallbladder problems, and potential thyroid concerns. All patients require thorough prescriber assessment and ongoing monitoring throughout treatment.

Managing Side Effects During Treatment

UK prescribers recommend several strategies to manage mounjaro vs wegovy side effects effectively. Starting with the lowest dose and following the prescribed escalation schedule allows gradual tolerance development. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated significantly reduce nausea and gastrointestinal discomfort. If side effects become intolerable, dose adjustment or temporary pause under prescriber guidance may be necessary before continuing treatment.

Dosing Schedule: Mounjaro vs Wegovy Administration Compared

The mounjaro vs wegovy dosing protocols differ in escalation speed and maximum maintenance dose. Mounjaro begins at 2.5mg weekly for four weeks, then increases to 5mg, with further escalation to 10mg or 15mg based on individual response and tolerability [1]. This relatively rapid titration allows patients to reach therapeutic doses within 8-20 weeks depending on target maintenance level.

Wegovy follows a more gradual escalation: 0.25mg weekly for four weeks, then 0.5mg, 1mg, 1.7mg, and finally 2.4mg maintenance dose over approximately 16-20 weeks [2]. This slower titration schedule may improve tolerability for patients particularly sensitive to gastrointestinal effects. Both medications are administered via subcutaneous injection once weekly, using pre-filled single-dose pens for convenient self-administration at home.

Cost Comparison: Mounjaro vs Wegovy UK Pricing

When comparing mounjaro vs wegovy cost in the UK, pricing varies by dose and supplier. At Cured Pharmacy, Mounjaro is available from £124.99 per month, whilst Wegovy starts from £124.99 monthly [4]. The price difference reflects manufacturing costs, market positioning, and dose strength variations between the two medications.

However, cost-effectiveness analysis should consider weight loss outcomes alongside price. Mounjaro's higher average weight loss (15-21%) compared to Wegovy (10-15%) may justify the additional cost for patients seeking maximum effectiveness [1][2]. Both treatments require long-term commitment for sustained results, and total treatment cost over 12-24 months represents a significant investment. Cured Pharmacy offers transparent upfront pricing and £20 off first orders with code Weightlossnew, making both options accessible to UK patients subject to prescriber approval.

Value for Money Considerations

Evaluating mounjaro vs wegovy value requires balancing effectiveness, tolerability, and budget. For patients who respond well to Wegovy and achieve their weight loss goals, the lower price point offers excellent value. Those requiring maximum weight reduction or who have not achieved adequate results with GLP-1-only treatments may find Mounjaro's dual-action mechanism worth the additional investment. UK prescribers can guide individualised treatment selection based on clinical history, BMI, comorbidities, and financial considerations during the online consultation process.

Which Treatment to Choose: Mounjaro vs Wegovy Suitability

Deciding between mounjaro vs wegovy depends on multiple clinical and personal factors. Mounjaro may be more suitable for patients with higher baseline BMI (≥35), those with type 2 diabetes requiring enhanced glycaemic control, or individuals who have not achieved adequate weight loss with GLP-1-only treatments [3]. The dual-receptor mechanism offers theoretical advantages for metabolic health beyond weight reduction alone.

Wegovy represents an excellent first-line option for patients new to GLP-1 therapy, those with BMI 30-35, or individuals prioritising cost-effectiveness with proven substantial weight loss results [2]. The established safety profile from years of semaglutide use (including Ozempic for diabetes) provides reassurance for both patients and prescribers. Both medications require prescription following clinical assessment by a UK-registered prescriber, who will evaluate medical history, current medications, contraindications, and individual treatment goals.

Personalised Treatment Selection at Cured Pharmacy

At Cured Pharmacy, our UK-registered clinical team conducts thorough online assessments to determine mounjaro vs wegovy suitability for each patient. Superintendent pharmacist Tarun Kumar (GPhC 2233073) and our prescribers review your complete medical profile, weight loss history, and treatment preferences before recommending the most appropriate option. The consultation takes under three minutes, and all genuine UK-licensed medications are dispensed with complete discretion and next-day delivery available. Both treatments require ongoing monitoring, and our clinical team remains available for dose adjustments and side effect management throughout your weight loss journey.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised trial. The Lancet, 398(10295), 143-155. [accessed 15 August 2026]
4. Cured Pharmacy. (2025). Weight loss treatment pricing and availability. Retrieved from https://curedpharmacy.com/collections/weight-loss [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.